Wainwright reiterates Dyne Therapeutics stock rating on trial outlook
H.C. Wainwright has maintained its Buy rating and $50 price target on Dyne Therapeutics (NASDAQ:DYN). The stock has grown 108% over the past year to $25.70, nearing its 52-week high with a market cap of $4.8 billion. Analysts see a strong buy consensus for the biotech company, focusing on the upcoming HARBOR trial results. H.C. Wainwright anticipates the HARBOR trial to meet its vHOT primary endpoint, based on the drug's mechanism and prior data.
Analysts also highlight Avidity's MARINA-OLE study, which demonstrated substantial improvements in multiple metrics. Despite the stock's valuation, H.C. Wainwright retains its positive outlook. Recent developments include a $300 million equity offering and FDA acceptance of Dyne's Biologics License Application for z-rostudirsen.
Analysts like Cantor Fitzgerald and TD Cowen have rated the stock positively, expressing confidence in Dyne's strategies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
